Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Taiwan's TLC Approved to Begin US Clinical Trials of Cancer Drug

publication date: Oct 3, 2016
TLC, a Taiwan novel drug developer, was approved to begin US trials of an oncology drug (TLC178), a lipid-encapsulated form of vinorelbine. Using its NanoX™ nanotechnology platform, TLC devised the lipid delivery formulation with the goal of targeting the chemotherapy and lowering its toxicity. TLC hopes the technology will increase the indications for TLC178 beyond non-small cell lung cancer (NSCLC) to lymphomas and other advanced solid tumors. More details....

Stock Symbol: (TT: 4152)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital